Peter Doshi outlines new concerns about the trustworthiness and meaningfulness of the reported efficacy results of Pfizer’s and Moderna’s COVID-19 vaccine trials.
Five weeks ago, when I raised questions about the results of Pfizer’s and Moderna’s COVID-19 vaccine trials, all that was in the public domain were the study protocols and a few press releases. Today, two journal publications and around 400 pages of summary data are available in the form of multiple reports presented by and to the FDA prior to the agency’s emergency authorization of each company’s mRNA vaccine. While some of the additional details are reassuring, some are not. Here I outline new concerns about the trustworthiness and meaningfulness of the reported efficacy results.
READ MORE
Image by Wilfried Pohnke from Pixabay